02:56 PM EST, 03/08/2024 (MT Newswires) -- Pulse Biosciences ( PLSE ) said Friday it has secured clearance from the US Food and Drug Administration for its CellFX nsPFA Percutaneous Electrode System for use in the ablation of soft tissue in percutaneous and intraoperative surgical procedures.

The CellFX nsPFA Percutaneous Electrode System consists of a percutaneous needle electrode for use with its CellFX nsPFA Console, the company said, adding that the percutaneous electrode is designed for non-cardiac applications.

Price: 9.50, Change: +0.05, Percent Change: +0.53